|
Valentis, Inc. - Comparative Business Analysis Snapshot
Business Description
Valentis, Inc.. The Group's principal activity is to develop products for peripheral arterial disease and is a clinical-stage biotechnology company. The Group focuses on research, preclinical and early stage clinical development of products in several therapeutic areas including cardiovascular disorders, oncology, haematology and immunology. The Group has three product platforms for the development of novel therapeutics namely the gene medicine, GeneSwitch (r) and DNA vaccine platforms. The Gene medicine platform includes a comprehensive array of proprietary nucleic acid delivery systems. GeneSwitch (r) platform controls erythropoietin protein production from an injected gene by orally administered drug. Synthetic vaccine delivery systems provide consistent levels of gene expression and enhance efficiency of plasmid.
Competitor Analysis
This analysis compares Valentis, Inc. with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
